infectious disease Archives - Amazing Health Advances

CDC Study: Significantly Higher Lyme Disease Rates Among Older Adults Than Previously Reported

The AHA! Team — Mon, 23 Sep 2024 08:24:32 +0000

Dr. Sanchari Sinha Dutta, Ph.D. via News-Medical – The U.S. Centers for Disease Control and Prevention (CDC), in association with the University of Iowa, USA, has conducted an epidemiological study to determine the incidence rate of Lyme disease among older adults in the United States. The study is published in the CDC’s Emerging Infectious Diseases journal. Background Lyme disease, also known as Lyme borreliosis, is a vector-borne bacterial infection caused by a species of Borrelia bacteria that spreads to humans by the bite of infected black-legged ticks (Ixodes scapularis). The main symptoms are fever, headache, fatigue, and a specific type of skin rash called erythema migrans. While Lyme disease can present with a characteristic erythema migrans rash, it can also lead to severe complications if left untreated, including facial nerve paralysis, arthritis, and even heart rhythm irregularities. In the United States, Lyme disease most commonly occurs in the Northeast, mid-Atlantic, and upper-Midwest regions. Previous studies estimating the prevalence of the disease have used employer-sponsored insurance claims data to quantify the disease diagnoses. However, this type of data does not include information on individuals aged 65 years and above who exhibit higher susceptibility to Lyme disease than their younger peers. In this study, scientists have determined the incidence of Lyme disease among older adults in the United States using Medicare fee-for-service data that includes information on individuals aged 65 years and above. Study design The study analyzed Medicare fee-for-service data together with drug treatment data to identify Lyme disease diagnoses among individuals aged 65 years and above. The data collected during 2016 – 2019 was included in the analysis. The Medicare fee-for-service study population was compared with the 2019 US Census estimation data for individuals aged 65 years and above to ensure that the two groups were age-, sex-, race-, ethnicity- and region-matched. Lyme disease diagnoses identified in the Medicare fee-for-service data were compared with the confirmed and probable cases among individuals aged 65 years and above obtained through national surveillance. However, the study also notes certain limitations, such as slight differences between the Medicare fee-for-service population and the U.S. Census population regarding race, ethnicity, and sex. These differences, though small, were stable throughout the study period. Important observations The Medicare fee-for-service population included in the study was estimated to have a median of 17,872,466 person-years during the study period, as compared to the US Census population of 51,561,372 individuals aged 65 years and above. Person-years refer to the number of years for which persons contribute data. The proportion of individuals from neighboring high-incidence states was higher in the Medicare population than in the US Census population. Incidence of Lyme disease A total of 88,485 Lyme disease cases were identified in the Medicare population during the 2016-2019 study period. This corresponded to an average incidence of 123.5 diagnoses per 100,000 person-years. The total number of Lyme disease cases reported through public health surveillance during the same period was 34,183. This corresponded to an average incidence of 16.6 cases per 100,000 persons. Symptoms include fever, headache, fatigue, and a bullseye rash. Approximately 82% of Lyme disease cases were identified among individuals residing in high-incidence states. The median incidence of Lyme disease diagnoses was 346.9 per 100,000 person-years among residents of high-incidence states, 35.3 per 100,000 person-years among residents of states or jurisdictions neighboring high-incidence states, and 29.4 per 100,000 person-years among residents of low-incidence states. Public health surveillance data revealed that about 93% of Lyme disease cases were among residents of high-incidence states. The median incidence of these cases was 57.1 per 100,000 persons among residents of high-incidence states, 3.6 per 100,000 persons among residents of states or jurisdictions neighboring high-incidence states, and 0.6 per 100,000 persons among residents of low-incidence states. The majority of Lyme disease diagnoses occurred in the summer months. Among residents of low-incidence states, a large proportion of disease diagnoses occurred in winter months. According to Medicare and surveillance data, the majority of Lyme disease cases were identified among men. In high-incidence states, men had the highest incidence of Lyme disease for all age groups. In low-incidence states, women had a slightly higher incidence than men only in the 65–69-year age group and 75–79-year age group. Study significance The study identified more than 88,000 adults aged 65 years and above diagnosed and treated with Lyme disease during 2016 – 2019 in the United States. Most Lyme disease cases have been identified among residents of high-incidence states. The study reports a 7-fold higher incidence of Lyme disease diagnoses compared to that reported through public health surveillance. These findings are similar to the findings reported in previous claims analyses. The study also acknowledges the issue of overdiagnosis, which may partly explain the differences observed between the Medicare data and public health surveillance data. Overdiagnosis has been reported in other analyses and may contribute to the higher incidence rates observed in this older population. A variation in Lyme disease seasonality has been observed when Medicare fee-for-service data is compared with surveillance data. Some differences in gender-specific disease susceptibility have also been observed when this study is compared with previous claims analyses. Antibiotics like doxycycline are effective treatments. In previous claims analyses, male children have shown higher susceptibility to Lyme disease in both high- and low-incidence states. In contrast, male older adults have shown higher susceptibility in high-incidence states. Overall, the study findings add insight into Lyme disease patterns unique to this older population in the United States. Journal reference: Schwartz AM. 2024. Epidemiology of Lyme Disease Diagnoses among Older Adults, United States, 2016–2019. Emerging Infectious Diseases. https://wwwnc.cdc.gov/eid/article/30/9/24-0454_article To read the original article click here.

The post CDC Study: Significantly Higher Lyme Disease Rates Among Older Adults Than Previously Reported appeared first on Amazing Health Advances.

Zinc Deficiency May Be Considered as a Risk Factor for Infectious Diseases

AHA Publisher — Wed, 15 Jul 2020 07:00:43 +0000

Sechenov University via EurekAlert – Researchers from Sechenov University in collaboration with colleagues from Germany, Greece and Russia reviewed scientific articles on the role of zinc in the prevention and treatment of viral infections and pneumonia, with projections on those caused by SARS-CoV-2. The results were published in the International Journal of Molecular Medicine. Zinc is necessary for normal metabolism and functioning of the reproductive, cardiovascular and nervous systems, but it is also important for the immune system, in particular for the proliferation and maturation of white blood cells (some of them are able to capture and digest microorganisms, and others – to produce antibodies). In addition, zinc is involved in the regulation of inflammation. Thus, normal levels of zinc support human resistance to inflammatory and infectious diseases. ‘According to the current estimates, the risk of zinc deficiency is observed in more than 1.5 billion people in the world. In Russia, deficiency of this element occurs in 20-40% of the population; in some regions it reaches 60%. Given the crucial role of zinc in regulation of immunity, one can propose that its insufficiency may be considered as a risk factor for infectious diseases,’ said the research leader, head of the Laboratory of Molecular Dietetics at Sechenov University, Professor Anatoly Skalny. The scientists reviewed the results of studies on the use of zinc-containing drugs for increasing immunity and preventing viral infections, including SARS-CoV-2 that caused COVID-19 outbreak this year. Previous studies showed that zinc and its binding substances can slow down the work of RNA polymerase (an enzyme that synthesises viral RNA molecules) of coronaviruses and suppress their spread in the body. One of the substances that stimulate the cellular zinc uptake, chloroquine, has already been tested on patients with SARS-CoV-2, but its strong side effects make it necessary to look for other compounds with a similar effect or use zinc separately. However, both options have not been sufficiently studied or tested yet. Observations of the development of other viruses, such as rhinoviruses (this family includes pathogens of acute respiratory diseases), show that an increase in the level of zinc in cells suppresses replication (reproduction) of the virus and stimulates production of interferon alpha, which has an antiviral activity. In addition, zinc deficiency is considered as one of the risk factors for the development of pneumonia: it increases the susceptibility to infectious agents and the disease duration. Several studies show the effectiveness of zinc-containing drugs in decreasing severity and duration of symptoms and reducing the prevalence of pneumonia. However, in general, data on the use of zinc as a therapy, rather than prevention, are contradictory. Another possible application of zinc is modulation of inflammation. Existing data show that zinc ions have an anti-inflammatory effect, reducing damage to lung tissue in pneumonia. Zinc also helps the body resist bacteria, and bacterial pneumonia frequently occurs in patients with secondary viral infections. ‘A recent study conducted by scientists from the USA confirmed our assumptions, demonstrating the effect of zinc intake on the risk of a severe course and the need for artificial ventilation in patients with COVID-19,’ said Alexey Tinkov, coauthor of the article, a leading researcher at the Laboratory of Molecular Dietetics at Sechenov University. Therefore, according to current research, adequate zinc status can bring down the likelihood of infectious respiratory diseases, pneumonia and its complications. There are also indirect indications that zinc intake may be effective in the fight against coronavirus disease (COVID-19), but there is still insufficient data for recommendations. To read the original article click here.

The post Zinc Deficiency May Be Considered as a Risk Factor for Infectious Diseases appeared first on Amazing Health Advances.

Boosting Antiviral Immune Function with Green Tea

AHA Publisher — Sun, 07 Jun 2020 07:00:28 +0000

Michael Greger M.D. FACLM via Nutrition Facts – Unlike most antiviral drugs, green tea appears to work by boosting the immune system to combat diseases such as genital warts (caused by HPV) and the flu (caused by the influenza virus). According to one study, “The belief in green tea as a ‘wonder weapon’ against diseases dates back thousands of years.” I’ve talked about it in relation to chronic disease, but what about infectious disease? I explore this in my video Benefits of Green Tea for Boosting Antiviral Immune Function. Interest in the antimicrobial activity of tea dates back to a military medical journal in 1906, which suggested that servicemen fill their canteens with tea to kill off the bugs that caused typhoid fever. “However, this effect of tea was not studied further until the late 1980s” when tea compounds were pitted against viruses and bacteria in test tubes and petri dishes, but what we care about is whether it works in people. I had dismissed this entire field of inquiry as clinically irrelevant until I learned about tea’s effect on genital warts. External genital warts, caused by human wart viruses, “are one of the most common and fastest-spreading venereal diseases worldwide.” Patients with external genital warts “present with one or several cauliflower-like growths on the genitals and/or anal regions…associated with…considerable impairment of patients’ emotional and sexual well-being.” But rub on some green tea ointment, and you can achieve complete clearance of all warts in more than 50 percent of cases. If it works so well for wart viruses, what about flu viruses? As you can see at 1:41 in my video, it works great in a petri dish, but what about in people? Well, tea-drinking school children seem to be protected, but you don’t know about the broader population until it’s put to the test. If you give healthcare workers green tea compounds, they come down with the flu about three times less often than those given placebo, as you can see at 2:02 in my video. In fact, just gargling with green tea may help. While a similar effect was not found in high school students, gargling with green tea may drop the risk of influenza infection seven or eight-fold compared to gargling with water in elderly residents of a nursing home, where flu can get really serious. Unlike antiviral drugs, green tea appears to work by boosting the immune system, enhancing the proliferation and activity of gamma delta T cells, a type of immune cell that acts as “a first line defense against infection.” According to the researchers, “Subjects who drank six cups of tea per day had up to a 15-fold increase in [infection-fighting] interferon gamma production in as little as one week”—but why There is in fact a molecular pattern shared by cancer cells, pathogens, and “edible plant products such as tea, apples, mushrooms, and wine.” So, eating healthy foods may help maintain our immune cells on ready alert, effectively priming our gamma delta T cells so they “then can provide natural resistance to microbial infections and perhaps tumors.” I guess I shouldn’t have been so surprised; tea, after all, is a “vegetable infusion.” You’re basically drinking a hot water extraction of a dark green leafy vegetable. To read the original article click here. For more articles from Dr. Greger click here.

The post Boosting Antiviral Immune Function with Green Tea appeared first on Amazing Health Advances.

Antiviral Compound Offers Hope Against Deadly Flu, Coronaviruses

AHA Publisher — Wed, 29 Jan 2020 08:00:23 +0000

Michigan Medicine – University of Michigan via Newswise – What keeps most infectious disease researchers up at night aren’t infamous viruses like Ebola. Instead, influenza, commonly known as the flu, continues to be a clear and present danger to humanity. Newswise — “Influenza is a huge problem, as the virus sickens or kills millions of people each year,” says David Markovitz, M.D., professor of internal medicine in the division of infectious diseases at Michigan Medicine. “A new pandemic along the lines of the 1918 Spanish flu has the potential to kill millions here and abroad.” To that end, he and an extensive team of collaborators have worked for years on broad-spectrum antiviral drugs developed from, of all things, banana plants. In a new paper published in the Proceedings of the National Academy of Sciences, Markovitz, first author Evelyn Coves-Datson, a M.D., Ph.D. student, Akira Ono, Ph.D., professor of microbiology and immunology and their team have shown that an engineered compound based on a banana lectin, a protein called H84T, has real potential for clinical use against influenza. In their experiments, more than 80% of mice exposed to a form of influenza that is typically fatal were able to survive the disease after receiving an injection of the protein, even up to 72 hours after exposure. The team also provides early evidence that the compound is safe. A downside of naturally occurring banana lectin—which can cause inflammation by inappropriately activating the immune system—wasn’t present in mice given H84T. Furthermore, because H84T is a protein, there was concern that the body would recognize it as foreign and develop antibodies against it, thereby neutralizing it or causing harm. The team found that while mice did develop antibodies against H84T, they didn’t appear to be adversely affected by them. The compound works because it targets a sugar called high mannose, which is present on the outside of certain viruses but not on most healthy cells. “We were able to show that H84T blocks the ability of the influenza virus to fuse with structures termed endosomes in the human cell, a key step in infection,” he explains. Doing so disabled their ability to replicate and wreak havoc. Amazingly, this mechanism of action, binding of high mannose sugars on the surface of viruses, means that H84T is effective not only against influenza, but also against Ebola, HIV, measles, MERS, a new deadly viral illness that was first reported in Saudi Arabia in 2012, SARS and all other coronaviruses tested. Even more promising is that the compound works where Tamiflu (oseltamivir), the current standard therapy for severe flu, has failed. “We’ve also shown that there may be a synergistic effect between H84T and Tamiflu,” says Markovitz. His team hopes to do more research with the compound in humans in the hopes of getting it to market. “We envision the government potentially stockpiling it in the event of a pandemic.” However, he says, “there are many difficulties to commercialization. Pharmaceutical economics do not seem to favor the development of antivirals or antibacterials for one-time usage, which is a huge problem.” To read the original article click here.

The post Antiviral Compound Offers Hope Against Deadly Flu, Coronaviruses appeared first on Amazing Health Advances.